Medtronic receives FDA approval for BrainSense Adaptive DBS technology
- Posted on March 3, 2025
- By Google News
- 2 Views
Medtronic receives FDA approval for BrainSense Adaptive DBS technology
For the one million people diagnosed with Parkinson's disease in the United States, Medtronic plc (NYSE:MDT), a global leader in healthcare technology, proudly announces U.S. Food and Drug Administration (FDA) approval of BrainSense™ Adaptive deep brain stimulation (aDBS) and BrainSense™ Electrode Identifier (EI).
